Moderate to Severe Acute Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Moderate to severe acute pain is characterized by a sudden or urgent onset and is typically associated with identifiable, treatable causes such as injury, trauma, surgery, or other medical interventions. Opioids are highly effective in managing acute nociceptive pain due to their potent analgesic properties. However, their use is accompanied by significant risks, including serious adverse effects and a high potential for abuse, addiction, and misuse. Despite these risks, opioid analgesics remain indispensable in the treatment of moderate to severe acute pain when non-pharmacological methods and non-opioid analgesics fail to provide adequate relief. Recent data indicate that the prevalence of opioid prescriptions for acute pain management remains substantial, with a continued emphasis on balancing effective pain control and minimizing the risk of opioid-related complications. According to the Centers for Disease Control and Prevention (CDC), in 2023, opioid prescribing rates have shown a slight decline due to increased awareness and regulatory measures. Yet, they remain a critical component in the therapeutic arsenal against acute pain. The current focus is on developing guidelines to optimize opioid use, ensuring that patients receive adequate pain relief while mitigating the risk of adverse outcomes.

Thelansis’s “Moderate to Severe Acute Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Acute Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Moderate to Severe Acute Pain across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Moderate to Severe Acute Pain Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Moderate to Severe Acute Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033